≡ MENU
Cell Therapies
Header5
Cell Therapies
Header4
Cell Therapies
Header1
Cell Therapies
Header2
Cell Therapies
Header3

CTPL CEO, Tim Oldham, elected to Alliance for Regenerative Medicine 2017 Board of Directors

October 26th, 2016 |

Melbourne, Australia, 11 October 2016: Cell Therapies Pty Ltd (CTPL) is pleased to announce that CEO and Managing Director Dr Tim Oldham has been elected to the Board of the Alliance for Regenerative Medicine (ARM) for 2017.

AusBiotech CEO Glenn Cross said: “On behalf of the Regenerative Medicine Advisory Group (RMAG) and AusBiotech, I would like to congratulate Tim Oldham on being elected to the Alliance for Regenerative Medicine 2017 Board of Directors. This is a prestigious position in an important and promising area of Australian medicine. Dr Oldham is a valuable member of the RMAG, and we look forward to working with Dr Oldham on future projects.”

ARM is the preeminent global advocate for regenerative and advanced therapies. ARM fosters research, development, investment and commercialization of transformational treatments and cures for patients worldwide. By leveraging the expertise of its membership, ARM empowers multiple stakeholders to promote legislative, regulatory and public understanding of, and support for, this expanding field. Based in Washington, DC, ARM promotes legislative, regulatory, reimbursement, investment, technical and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understanding of the field and its potential to transform human healthcare.

“ARM leadership reflects the geographical and technological diversity of our membership,” said Morrie Ruffin, managing director of ARM in ARM’s announcement of the 2017 leadership. “We welcome these new slates of officers, directors and executive committee members; each has demonstrated direct involvement and active participation in ARM’s activities and has made vital contributions to the advancement of this sector.”

“I look forward to continuing CTPL’s significant contribution to our industry through this appointment, and in particular to increasing the voice and profile of AusBiotech’s Regenerative Medicine Advisory Group and the Australian industry in general” said Dr Oldham.

http://alliancerm.org/press/alliance-regenerative-medicine-announces-election-2017-arm-officers%2C-executive-committee-and